Evidence map›Paper›PMID 22713481›Full record

ArticleDiagnostic pathology2012

Oncogenic reg IV is a novel prognostic marker for glioma patient survival.

Qi Wang, Jianping Deng, Jun Yuan, Liang Wang, Zhenwei Zhao, Shiming He, Yongsheng Zhang, Yanyang Tu

Open access · goldAbstract read
In one paragraph

Article in Diagnostic pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Herbal medicine,Frontiers in pharmacology · 2023
    Pooled it
  3. Review
  4. Article
  5. REG4 promotes the proliferation and anti-apoptosis of cancer.Frontiers in cell and developmental biology · 2022
    Review
  6. Okamoto model for necrosis and its expansions, CD38-cyclic ADP-ribose signal system for intracellular CaProceedings of the Japan Academy. Series B, Physical and biological sciences · 2021
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Qi WangDepartment of Experimental Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an City 710032, China.
Jianping Deng
Jun Yuan
Liang Wang
Zhenwei Zhao
Shiming He
Yongsheng Zhang
Yanyang Tu
Air Force Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe aberrant expression of regenerating islet-derived family member, 4 (Reg IV) has been found in various human cancers. However, the roles of Reg IV gene and its encoding product in human glioma have not been clearly understood. Therefore, the aim of this study was to investigate the clinicopathological significance of Reg IV expression in glioma.

methodsReg IV mRNA and protein expression in human gliomas and non-neoplastic brain tissues were respectively detected by real-time quantitative RT-PCR assay, Western blot, and immunohistochemistry. The association of Reg IV immunostaining with clinicopathological factors and prognosis of glioma patients was also statistically analyzed.

resultsReg IV mRNA and protein expression levels in glioma tissues were both significantly higher than those in the corresponding non-neoplastic brain tissues (both P < 0.001). Additionally, the increased Reg IV immunostaining in glioma tissues was significantly associated with advanced pathological grade (P = 0.008). Reg IV protein up-regulation was also significantly correlated with low Karnofsky performance score (KPS) (P = 0.02). Moreover, the overall survival of patients with high Reg IV protein expression was dramatically shorter than those with low Reg IV protein expression (P < 0.001). Multivariate Cox regression analysis further confirmed that Reg IV expression was an independent prognostic factor for patients with gliomas (P = 0.008).

conclusionsThese convinced evidences suggest for the first time that Reg IV might accelerate disease progression and act as a candidate prognostic marker for gliomas. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/2145344361720706.

Indexed as

AdolescentAdultAgedBiomarkers, TumorBlotting, WesternBrain NeoplasmsChildFemaleGliomaHumansImmunohistochemistryKaplan-Meier EstimateKarnofsky Performance StatusLectins, C-TypeMaleMiddle AgedBiomarkers, TumorLectins, C-TypePancreatitis-Associated ProteinsREG4 protein, humanRNA, Messenger

Identifiers

PMID22713481
PMCPMC3465175
OpenAlexW2103075925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.